955376-51-9

Basic information

• Product Name: IMidazo[1,2-a]pyridine,6-Methoxy-
• Synonyms: IMidazo[1,2-a]pyridine,6-Methoxy-;6-MethoxyiMidazo[1,2-a]pyridine
• CAS NO: 955376-51-9
• Molecular Formula: C8H8N2O
• Molecular Weight: 148.16192
• Mol File: 955376-51-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.18g/cm³
• Refractive Index: 1.594
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.28±0.50(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyridine,6-Methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine,6-Methoxy-(955376-51-9)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine,6-Methoxy-(955376-51-9)

Safety Data

• Hazardous Substances Data: 955376-51-9(Hazardous Substances Data)

Usage

Uses

6-Methoxyimidazo[1,2-a]pyridine are?imidazopyridines. This class of compounds are suggested to?inhibit?interleukin-1 receptor-associated kinase 4 (IRAK-4), which is a protein kinase involved in the signalling of innate immune response from Toll-like receptors (TLR). It can also be used to synthesize c-Met Inhibitors that have potential therapeutic applications for cancer treatment.

InChI:InChI=1/C8H8N2O/c1-11-7-2-3-8-9-4-5-10(8)6-7/h2-6H,1H3

Upstream product

• 107-20-0 2-chloroethanal 
• 10167-97-2 2-amino-5-methoxypyridine 
• 67-56-1 methanol 
• 426825-75-4 6-iodoimidazo[1,2-a]pyridine 
• 6602-32-0 2-bromo-pyridin-3-ol 
• 24100-18-3 2-bromo-3-methoxypyridine 
• 76066-07-4 2-bromo-3-methoxy-6-nitropyridine 

Downstream Products

• 1100750-16-0 5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-ol 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING

Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.

[5,6]HETEROCYCLIC COMPOUND

Abstract: An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R1 and R2 represent hydrogen atoms, and the like; R3 represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.